Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells.
about
Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancerProtein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthaseTranscriptional activation and cell cycle block are the keys for 5-fluorouracil induced up-regulation of human thymidylate synthase expression.Distamycin A and derivatives as synergic drugs in cisplatin-sensitive and -resistant ovarian cancer cells.
P2860
Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Collateral sensitivity to nove ...... nt human ovarian cancer cells.
@en
Collateral sensitivity to nove ...... nt human ovarian cancer cells.
@nl
type
label
Collateral sensitivity to nove ...... nt human ovarian cancer cells.
@en
Collateral sensitivity to nove ...... nt human ovarian cancer cells.
@nl
prefLabel
Collateral sensitivity to nove ...... nt human ovarian cancer cells.
@en
Collateral sensitivity to nove ...... nt human ovarian cancer cells.
@nl
P2093
P50
P1476
Collateral sensitivity to nove ...... nt human ovarian cancer cells.
@en
P2093
Alessio Ligabue
Davide Guerrieri
Gabriella Vitale
Giuseppe Paglietti
Maria Stella Moruzzi
Paola Corona
Sandra Piras
P356
10.1016/J.EJPHAR.2009.04.062
P407
P577
2009-05-14T00:00:00Z